A recent paper by Charles Geyer Jr., Chief Scientific Officer of NSABP Foundation, was mentioned by Yakup Ergün, Medical Oncologist at Antalya City Hospital, on X:
“Survival with T-DM1 in Residual HER2-Positive Breast Cancer (KATHERINE)
mFU: 8.4 years
- 7y-iDFS – 80.8 vs 67.1%
- 7y-OS – 89.1 vs 84.4%.”
“Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer”
Authors: Charles Geyer Jr. et al.
More posts featuring Yakup Ergün.